Site search

Clear filter
2893 results for '' found
A PHASE 1, OPEN-LABEL DOSE ESCALATION AND EXPANSION STUDY OF SNV1521 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS (NCT06220864)
A PHASE 1, OPEN-LABEL DOSE ESCALATION AND EXPANSION STUDY OF SNV1521 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS (NCT06220864)
/
Stereotactic ablative body radiation therapy with Nodal Irradiation for ProstatE canceR (ACTRN12625000259448)
Stereotactic ablative body radiation therapy with Nodal Irradiation for ProstatE canceR (ACTRN12625000259448)
/
Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with
/
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or
/
Sugammadex, neostigmine and postoperative pulmonary complications (the SNaPP Study) (ACTRN12623000394640)
/
Staphylococcus aureus Network Adaptive Platform trial (SNAP) (NCT05137119)
Staphylococcus aureus Network Adaptive Platform trial (SNAP) (NCT05137119)
/
SMITE: Superiority of Migraine Inpatient Treatment with Eptinezumab (ACTRN12621001616864)
SMITE: Superiority of Migraine Inpatient Treatment with Eptinezumab (ACTRN12621001616864)
/
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)
/
A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) (NCT02821013)
/
Switching patients from intravenous to subcutaneous infliximab in inflammatory bowel disease (ACTRN12621001498886)
Switching patients from intravenous to subcutaneous infliximab in inflammatory bowel disease (ACTRN12621001498886)
/
20 21 22 23 24